AllianceBernstein
CARM

AllianceBernstein’s Carisma Therapeutics CARM Stock Holding History

AllianceBernstein’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,715
Closed -$93K – 3278
2022
Q1 		$93K Buy
7,715
+25
+0.3% +$349 ﹤0.01% 3122
2021
Q4 		$125K Hold
7,690
– – ﹤0.01% 3165
2021
Q3 		$122K Hold
7,690
– – ﹤0.01% 3164
2021
Q2 		$711K Buy
+7,690
New +$490K ﹤0.01% 2670
2015
Q2 		– Sell
-15
Closed -$3K – 3038
2015
Q1 		$3K Hold
15
– – ﹤0.01% 3457
2014
Q4 		$4K Hold
15
– – ﹤0.01% 3380
2014
Q3 		$3K Sell
15
-15
-50% -$3.56K ﹤0.01% 3369
2014
Q2 		$8K Buy
+30
New +$7.42K ﹤0.01% 3329

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

AllianceBernstein's CARM Position: Q2 2022 in Review

AllianceBernstein sold out of Carisma Therapeutics (CARM) in Q2 2022, closing a stake of 7,715 shares — an estimated $93K sold.

AllianceBernstein first reported a position in CARM in Q2 2014 and held it in 8 quarters. The position peaked at $711K in Q2 2021. 73 funds tracked by Wall St. Rank hold CARM as of Q2 2022.

  • AllianceBernstein reported no remaining Carisma Therapeutics position as of Q2 2022 after selling out during the quarter.
  • AllianceBernstein sold 7,715 Carisma Therapeutics shares in Q2 2022, an estimated $93K.
  • AllianceBernstein first reported a position in Carisma Therapeutics in Q2 2014 and held it in 8 quarters.
  • AllianceBernstein's Carisma Therapeutics position peaked at $711K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.